Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Vertex Pharmaceuticals Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

	Jun 30, 2026	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021
Accounts payable	429,500)	489,300)	461,700)	420,300)	442,300)	445,000)	413,000)	395,800)	327,900)	351,400)	364,900)	375,900)	363,000)	323,200)	303,900)	126,900)	198,000)	173,600)	195,000)	127,863)	127,534)	127,839)
Accrued expenses	3,179,000)	2,984,200)	2,971,200)	3,613,500)	3,270,700)	2,951,800)	2,788,600)	3,219,700)	2,940,000)	2,795,900)	2,655,300)	2,907,300)	2,598,100)	2,326,000)	2,126,700)	2,264,400)	2,119,500)	1,720,500)	1,678,600)	1,584,992)	1,482,556)	1,532,037)
Other current liabilities	329,400)	407,100)	428,300)	441,500)	425,400)	386,400)	363,000)	357,600)	279,300)	648,600)	527,200)	316,200)	391,000)	377,000)	311,500)	218,000)	238,700)	286,100)	268,400)	201,409)	226,358)	284,174)
Current liabilities	3,937,900)	3,880,600)	3,861,200)	4,475,300)	4,138,400)	3,783,200)	3,564,600)	3,973,100)	3,547,200)	3,795,900)	3,547,400)	3,599,400)	3,352,100)	3,026,200)	2,742,100)	2,609,300)	2,556,200)	2,180,200)	2,142,000)	1,914,264)	1,836,448)	1,944,050)
Long-term operating lease liabilities	1,977,600)	1,986,500)	1,846,500)	1,834,800)	1,527,400)	1,537,700)	1,544,400)	1,588,900)	586,800)	359,800)	348,600)	354,400)	363,500)	371,600)	379,500)	382,300)	365,000)	377,000)	377,400)	363,545)	368,924)	368,467)
Other long-term liabilities	1,259,900)	1,255,400)	1,269,500)	1,233,400)	1,195,500)	1,063,300)	1,014,600)	1,047,300)	1,223,400)	1,215,100)	1,253,800)	1,259,600)	1,163,400)	1,144,100)	1,116,600)	685,200)	727,500)	791,900)	813,100)	810,228)	819,918)	822,288)
Long-term liabilities	3,237,500)	3,241,900)	3,116,000)	3,068,200)	2,722,900)	2,601,000)	2,559,000)	2,636,200)	1,810,200)	1,574,900)	1,602,400)	1,614,000)	1,526,900)	1,515,700)	1,496,100)	1,067,500)	1,092,500)	1,168,900)	1,190,500)	1,173,773)	1,188,842)	1,190,755)
Total liabilities	7,175,400)	7,122,500)	6,977,200)	7,543,500)	6,861,300)	6,384,200)	6,123,600)	6,609,300)	5,357,400)	5,370,800)	5,149,800)	5,213,400)	4,879,000)	4,541,900)	4,238,200)	3,676,800)	3,648,700)	3,349,100)	3,332,500)	3,088,037)	3,025,290)	3,134,805)
Preferred stock, $0.01 par value; none issued	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Common stock, $0.01 par value	2,500)	2,500)	2,500)	2,500)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,600)	2,500)	2,562)	2,591)	2,588)
Additional paid-in capital	4,505,700)	4,743,200)	5,119,200)	5,011,900)	5,987,900)	6,172,500)	6,672,400)	6,905,700)	7,101,200)	7,284,700)	7,449,700)	7,339,600)	7,369,100)	7,220,200)	7,386,500)	7,225,500)	7,100,000)	6,930,200)	6,880,800)	7,085,950)	7,640,233)	7,499,161)
Accumulated other comprehensive income (loss)	48,500)	24,800)	(15,900)	(64,500)	(101,100)	68,100)	127,800)	28,800)	22,500)	17,300)	(14,300)	(3,000)	(39,800)	(13,100)	800)	97,600)	57,500)	11,300)	15,900)	11,537)	(25,159)	(33,302)
Retained earnings	15,691,200)	14,591,400)	13,560,000)	12,368,900)	11,286,000)	10,253,100)	9,606,800)	8,693,800)	7,648,400)	11,242,000)	10,142,400)	9,173,600)	8,138,300)	7,222,600)	6,522,800)	5,703,900)	4,773,400)	3,962,900)	3,200,800)	2,430,659)	1,578,731)	1,511,807)
Shareholders’ equity	20,247,900)	19,361,900)	18,665,800)	17,318,800)	17,175,400)	16,496,300)	16,409,600)	15,630,900)	14,774,700)	18,546,600)	17,580,400)	16,512,800)	15,470,200)	14,432,300)	13,912,700)	13,029,600)	11,933,500)	10,907,000)	10,100,000)	9,530,708)	9,196,396)	8,980,254)
Total liabilities and shareholders’ equity	27,423,300)	26,484,400)	25,643,000)	24,862,300)	24,036,700)	22,880,500)	22,533,200)	22,240,200)	20,132,100)	23,917,400)	22,730,200)	21,726,200)	20,349,200)	18,974,200)	18,150,900)	16,706,400)	15,582,200)	14,256,100)	13,432,500)	12,618,745)	12,221,686)	12,115,059)

A significant expansion of the total balance sheet is evident from March 31, 2021, through June 30, 2026, with total liabilities and shareholders' equity increasing from approximately 12.1 billion USD to 27.4 billion USD. This growth is characterized by a substantial increase in retained earnings and a steady rise in total liabilities, indicating a period of aggressive scaling and capital accumulation.

Liability Structure and Trends: Total liabilities grew from 3.13 billion USD in March 2021 to 7.18 billion USD by June 2026. Current liabilities exhibited a consistent upward trajectory, rising from 1.94 billion USD to 3.94 billion USD. This growth was primarily driven by accrued expenses, which more than doubled from 1.53 billion USD to 3.18 billion USD over the analyzed period.; A notable shift occurred in long-term liabilities, which increased from 1.19 billion USD to 3.24 billion USD. Specifically, long-term operating lease liabilities remained relatively stable around 350 million to 380 million USD until June 30, 2024, at which point a sharp increase was observed, peaking at approximately 1.98 billion USD by March 31, 2026. This suggests a significant expansion in leased assets or a restructuring of lease agreements during the 2024-2026 period.
Shareholders' Equity and Capital Composition: Total shareholders' equity experienced robust growth, increasing from 8.98 billion USD in March 2021 to 20.25 billion USD in June 2026. The primary driver of this increase was retained earnings, which surged from 1.51 billion USD to 15.69 billion USD, reflecting strong internal profit generation and retention.; Conversely, additional paid-in capital showed a long-term declining trend, decreasing from a peak of 7.50 billion USD in March 2021 to 4.51 billion USD by June 2026. This inverse relationship between retained earnings and paid-in capital indicates a transition toward a self-sustaining capital structure where organic growth outweighs external equity financing, potentially including the impact of share repurchases.

The overall financial position demonstrates a stable leverage profile. While total liabilities increased, they grew at a slower pace than shareholders' equity. The ratio of total liabilities to total equity remained relatively constant over the period, suggesting that the company has managed to scale its operations and obligations without compromising its solvency or significantly increasing its financial risk relative to its equity base.

AI Ask an analyst for more

Download chart

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Balance Sheet: Liabilities and Stockholders’ Equity Quarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data